ALN-4324: ALN-4324 will be administered subcutaneously (SC).
Placebo: Placebo will be administered SC.
Study summary
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Is an adult patient with a confirmed diagnosis of T2DM
* Has a body mass index (BMI) of ≥23 kg/m\^2 to ≤39.9 kg/m\^2
* Has a hemoglobin A1c (HbA1c) ≥6.5% to \<10.5%
* Is on a stable dose of metformin, sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase-4 inhibitor (DPP4i)
Exclusion Criteria:
* Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
* Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods
Note: other protocol defined inclusion/exclusion criteria apply
Primary outcome measure(s)
Change from Baseline in M-value — Baseline up to Month 3 M-value is measured as the glucose infusion rate at steady state
Trial sites (1)
Facility
City
Region
Status
Clinical Trial Site
Chula Vista
California
Recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.